# US 2012/0232093 A1 · Pyrazole derivatives as sigma receptor inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232093 A1
- Document ID: US20120232093A1
- Status: Published application
- Kind: A1
- Application number: 13/479,352
- Filed: 2012-05-24
- Published: 2012-09-13
- Earliest claimed: 2006-03-01
- Assignees: Laboratorios Del Dr. Esteve, S.A.
- Inventors: Rosa CUBERES-ALTISENT; Joerg HOLENZ
- Web page: https://patentgrep.com/patent/US20120232093A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 231/22: with aryl radicals attached to ring nitrogen atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to compounds of formula I having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

A method of treating or preventing a sigma receptor mediated disease or condition, said method comprising administering to a patient in need of such a treatment or prevention a therapeutically effective amount of a compound of formula (I):
wherein
R1 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen;
R2 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —S(O)t—R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen;
Y is selected from substituted or unsubstituted phenyl or naphthyl;
X is selected from:
—CH2-Het-CHRx—,
—CH2—CHRx-Het-,
-Het-CH2—CHRx—,
—CH2—CH2—CHRx—, or
—CH2—CHRx—CH2—,
with
Het being NH, S or O,
—CHRx— being
wherein
R5 and R6, identical or different, represent a hydrogen atom; an optionally substituted C1-4 alkyl group; an optionally substituted aryl group; an optionally substituted heteroaryl group; a C1-4 alkoxy group; a benzyl group; a phenethyl group;
or
form, together with their bridging nitrogen atom, an optionally substituted heteroaryl group which is optionally condensed to other, optionally at least one heteroatom containing mono- or polycyclic ring system which is optionally at least mono-substituted;
or
X is selected from:
—CH2-Het-CHRx—,
—CH2—CHRx-Het-,
-Het-CH2—CHRx—,
—CH2—CH2—CHRx—,
—CH2—CHRx—CH2—,
—CH2—CH2—NRx—, or
—CH2—NRx—CH2—,
with
Het being NH, S or O,
Rx, being a —(C═O)—R10; or a —(C═O)—O—R11 group; wherein
R10 and R11 independently represent a hydrogen atom; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl group; an optionally at least mono-substituted aryl group; an optionally at least mono-substituted heteroaryl group; an optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloalkyl group; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-aryl group; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-heteroaryl group; or a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-cycloalkyl group wherein the cycloalkyl group contains optionally at least one heteroatom as ring member;
n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
t is 1, 2 or 3;
R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, or halogen;
optionally in form of a racemate in any mixing ratio, or a corresponding salt thereof.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the compound of formula I comprises a compound of formula IB:
wherein
R1 is selected from the group formed by hydrogen; substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9 or halogen,
R2 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —S(O)t—R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen;
R3 and R4 are independently selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —S(O)t—R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen, or together with the phenyl ring to which they are attached they form a substituted or unsubstituted naphthyl ring,
X is selected from:
—CH2-Het-CHRx—,
—CH2—CHRx-Het-,
-Het-CH2—CHRx—,
—CH2—CH2—CHRx—, or
—CH2—CHRx—CH2—,
with
Het being NH, S or O,
—CHRx— being
wherein
R5 and R6, identical or different, represent a hydrogen atom; an optionally substituted C1-4 alkyl group; an optionally substituted aryl group; an optionally substituted heteroaryl group; a C1-4 alkoxy group; a benzyl group; a phenethyl group;
or
form, together with their bridging nitrogen atom, an optionally substituted heteroaryl group which is optionally condensed to other, optionally at least one heteroatom containing mono- or polycyclic ring system which is optionally at least mono-substituted;
or
X is selected from:
—CH2-Het-CHRx—,
—CH2—CHRx-Het-,
-Het-CH2—CHRx—,
—CH2—CH2—CHRx—,
—CH2—CHRx—CH2—,
—CH2—CH2—NRx—, or
—CH2—NRx—CH2—,
with
Het being NH, S or O,
Rx being a —(C═O)—R10; or a —(C═O)—O—R11 group; wherein
R10 and R11 independently represent a hydrogen atom; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl group; an optionally at least mono-substituted aryl group; an optionally at least mono-substituted heteroaryl group; an optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloalkyl group; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-aryl group; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-heteroaryl group; or a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-cycloalkyl group wherein the cycloalkyl group contains optionally at least one heteroatom as ring member;
n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
t is 1, 2 or 3;
R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, or halogen;
optionally in form of a racemate in any mixing ratio, or a corresponding salt thereof.

### Claim 29 (depends on 27)

The method according to claim 27, wherein the compound of formula I comprises:
wherein
R1 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen;
R2 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —S(O)t—R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen;
Y is selected from substituted or unsubstituted phenyl or naphtyl;
X is selected from:
—CH2-Het-CHRx—,
—CH2—CHRx-Het-,
-Het-CH2—CHRx—,
—CH2—CH2—CHRx—, or
—CH2—CHRx—CH2—,
with
Het being NH, S or O,
—CHRx— being
wherein
R5 and R6, identical or different, represent a hydrogen atom; an optionally substituted C1-4 alkyl group; an optionally substituted aryl group; an optionally substituted heteroaryl group; a C1-4 alkoxy group; a benzyl group; a phenethyl group;
or
form, together with their bridging nitrogen atom, an optionally substituted heteroaryl group which is optionally condensed to other, optionally at least one heteroatom containing mono- or polycyclic ring system which is optionally at least mono-substituted;
n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
t is 1, 2, or 3;
R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, or halogen;
optionally in form of a racemate in any mixing ratio, or a corresponding salt thereof.

### Claim 30 (depends on 28)

The method according to claim 28, wherein the compound of formula IB comprises:
wherein
R1 is selected from the group formed by hydrogen; substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9 or halogen,
R2 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —S(O)t—R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen;
R3 and R4 are independently selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —S(O)t—R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen, or together with the phenyl ring to which they are attached they form a substituted or unsubstituted naphthyl ring,
X is selected from:
—CH2-Het-CHRx—,
—CH2—CHRx-Het-,
-Het-CH2—CHRx—,
—CH2—CH2—CHRx—, or
—CH2—CHRx—CH2—,
with
Het being NH, S or O, —CHRx— being
with
R5 and R6, identical or different, represent a hydrogen atom; an optionally substituted C1-4 alkyl group; an optionally substituted aryl group; an optionally substituted heteroaryl group; a C1-4 alkoxy group; a benzyl group; a phenethyl group;
or
form, together with their bridging nitrogen atom, an optionally substituted heteroaryl group which is optionally condensed to other, optionally at least one heteroatom containing mono- or polycyclic ring system which is optionally at least mono-substituted;
n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
t is 1, 2 or 3;
R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, or halogen;
optionally in form of a racemate in any mixing ratio, or a corresponding salt thereof.

### Claim 31 (depends on 27)

The method according to claim 27, wherein the compound of formula I comprises:
wherein
R1 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen;
R2 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —S(O)t—R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen;
Y is selected from substituted or unsubstituted phenyl or naphtyl;
X is selected from:
—CH2-Het-CHRx—,
—CH2—CHRx-Het-,
-Het-CH2—CHRx—,
—CH2—CH2—CHRx—,
—CH2—CHRx—CH2—,
—CH2—CH2—NRx—, or
—CH2—NRx—CH2—,
with
Het being NH, S or O,
Rx being a —(C═O)—R10; or a —(C═O)—O—R11 group;
and
R10 and R11 independently represent a hydrogen atom; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl group; an optionally at least mono-substituted aryl group; an optionally at least mono-substituted heteroaryl group; an optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloalkyl group; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-aryl group; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-heteroaryl group; or a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-cycloalkyl group wherein the cycloalkyl group contains optionally at least one heteroatom as ring member;
n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
t is 1, 2 or 3;
R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, or halogen;
optionally in form of a racemate in any mixing ratio, or a corresponding salt thereof.

### Claim 32 (depends on 28)

The method according to claim 28, wherein the compound of formula IB comprises:
wherein
R1 is selected from the group formed by hydrogen; substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9 or halogen,
R2 is selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —S(O)t—R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen;
R3 and R4 are independently selected from the group formed by hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, —COR8, —C(O)OR8, —C(O)NR8R9—C═NR8, —CN, —OR8, —OC(O)R8, —S(O)t—R8, —NR8R9, —NR8C(O)R9, —NO2, —N═CR8R9, or halogen, or together with the phenyl ring to which they are attached they form a substituted or unsubstituted naphthyl ring,
X is selected from:
—CH2-Het-CHRx—,
—CH2—CHRx-Het-,
-Het-CH2—CHRx—,
—CH2—CH2—CHRx—,
—CH2—CHRx—CH2—,
—CH2—CH2—NRx—, or
—CH2—NRx—CH2—,
with
Het being NH, S or O,
Rx being a —(C═O)—R10; or a —(C═O)—O—R11 group;
and
R10 and R11 independently represent a hydrogen atom; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl group; an optionally at least mono-substituted aryl group; an optionally at least mono-substituted heteroaryl group; an optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloalkyl group; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-aryl group; a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-heteroaryl group; or a saturated or unsaturated, optionally at least mono-substituted C1-6 alkyl-cycloalkyl group wherein the cycloalkyl group contains optionally at least one heteroatom as ring member;
n is selected from 1, 2, 3, 4, 5, 6, 7 or 8;
t is 1, 2 or 3;
R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, or halogen;
optionally in form of a racemate in any mixing ratio, or a corresponding salt thereof.

### Claim 33 (depends on 27)

The method according to claim 27, wherein the compound of formula I is characterized in that R1 is selected from H, halogen, —COR8, or substituted or unsubstituted alkyl, preferably it is selected from H, Cl, methyl or acetyl.

### Claim 34 (depends on 27)

The method according to claim 27, wherein the compound of formula I is characterized in that R1 is hydrogen.

### Claim 35 (depends on 27)

The method according to claim 27, wherein the compound of formula I is characterized in that R2 is H, aryl, C(O)OR8 or alkyl, preferably methyl, iso-propyl, phenyl, C(O)O—C2H5 or H.

### Claim 36 (depends on 28)

The method according to claim 28, wherein the compound of formula IB is characterized in that R3 and R4 are situated in the meta and para positions of the phenyl group.

### Claim 37 (depends on 28)

The method according to claim 28, wherein the compound of formula IB is characterized in that R3 and R4 are independently selected from halogen, hydrogen, alkoxy, or substituted or unsubstituted alkyl, more preferably selected from hydrogen, halogen, Cl, methoxy or haloalkyl.

### Claim 38 (depends on 28)

The method according to claim 28, wherein the compound of formula IB is characterized in that R3 and R4 together with the phenyl ring to which they are attached form a substituted or unsubstituted naphthyl-radical.

### Claim 39 (depends on 27)

The method according to claim 27, wherein the compound of formula I is characterized in that n is selected from 2, 3, and 4.

### Claim 40 (depends on 27)

The method according to claim 27, wherein the compound of formula I is characterized in that X is selected from the group consisting of
—CH2—CH2—CHRx—, and
—CH2—CHRx—CH2—.

### Claim 41 (depends on 27)

The method according to claim 27, wherein the compound of formula I is characterized in that R5 and R6 are selected from hydrogen or alkyl
or
form, together with their bridging nitrogen atom, an optionally substituted heteroaryl group which is optionally condensed to other, optionally at least one heteroatom containing mono- or polycyclic ring system which is optionally at least mono-substituted, especially an indazole or an 1H-indazole.

### Claim 42 (depends on 27)

The method according to claim 27, wherein the compound of formula I is characterized in that the compound is selected from the group consisting of:
3-{1-[2-(1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl]piperidin-4-yl}-3H-imidazo[4,5-b]pyridine, and
3-{1-[2-(1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl]piperidin-4-yl}-3H-imidazo[4,5-b]pyridine oxalate,
optionally in form of a racemate in any mixing ratio, or a corresponding salt thereof.

### Claim 43 (depends on 27)

The method according to claim 27, wherein the compound of formula I is characterized in that X is selected from the group consisting of
—CH2—CH2—NRx—, and
—CH2—NRx—CH2—.

### Claim 44 (depends on 27)

The method according to claim 27, wherein the compound of formula I is characterized in that R10 and R11 are independently selected from hydrogen or alkyl.

### Claim 45 (depends on 27)

The method according to claim 27, wherein the compound of formula I is characterized in that the compound is selected from the group consisting of
1-(4-(2-(1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl)piperazin-1-yl)ethanone,
1-(4-(2-(1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl)piperazin-1-yl)ethanone oxalate,
1-{1-[2-(1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy)ethyl]piperidin-4-yl}ethanone,
1-{1-[2-(1-(3,4-Dichlorophenyl)-1H-pyrazol-3-yloxy)ethyl]piperidin-4-yl}ethanone oxalate,
1-{4-[2-(1-(3,4-Dichlo-rophenyl)-1H-pyrazol-3-yloxy)ethyl]piperazin-1-yl}ethanone,
1-{4-[2-(1-(3,4-Dichlo-rophenyl)-1H-pyrazol-3-yloxy)ethyl]piperazin-1-yl}ethanone oxalate,
1-(1-[2-{1-(2,4-Dichlo-rophenyl)-1H-pyrazol-3-yloxy}ethyl]piperidin-4-yl)ethanone,
1-(1-[2-{1-(2,4-Dichlo-rophenyl)-1H-pyrazol-3-yloxy}ethyl]piperidin-4-yl)ethanone oxalate,
1-(1-(2-(1-(4-Chloro-phenyl)-1H-pyrazol-3-yloxy)ethyl)piperidin-4-yl)ethanone,
1-(1-(2-(1-(4-Chloro-phenyl)-1H-pyrazol-3-yloxy)ethyl)piperidin-4-yl)ethanone oxalate,
1-(1-(2-(1-(3,4-Dichlo-rophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl)piperidin-4-yl)ethanone,
1-(1-(2-(1-(3,4-Dichlo-rophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl)piperidin-4-yl)ethanone oxalate,
1-(4-(4-(1-(3,4-Dichlo-rophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy)butyl)piperazin-1-yl)ethanone,
1-(4-(4-(1-(3,4-Dichlo-rophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy)butyl)piperazin-1-yl)ethanone oxalate,
1-(4-(2-(1-(2,4-Dichlo-rophenyl)-1H-pyrazol-3-yloxy)ethyl)piperazin-1-yl)ethanone,
1-(4-(2-(1-(2,4-Dichlo-rophenyl)-1H-pyrazol-3-yloxy)ethyl)piperazin-1-yl)ethanone oxalate,
1-(4-(2-(1-(3,4-Dichlo-rophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy)ethyl)piperazin-1-yl)ethanone,
1-(4-(2-(1-(3,4-Dichlo-rophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy)ethyl)piperazin-1-yl)ethanone oxalate,
1-(4-{4-[1-(3,4-Dichloro-phenyl)-5-methyl-1H-pyrazol-3-yloxy]-butyl}-piperazin-1-yl)-ethanone, and
1-(4-{4-[1-(3,4-Dichloro-phenyl)-5-methyl-1H-pyrazol-3-yloxy]-butyl}-piperazin-1-yl)-ethanone oxalate;
optionally in form of a racemate in any mixing ratio, or a corresponding salt thereof.

### Claim 46 (depends on 1, 27)

The method according to claim 27, wherein the compound of formula I is provided as a pharmaceutical composition which comprises a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

### Claim 47 (depends on 27)

The method according to claim 27, wherein the disease is diarrhoea, lipoprotein disorders, metabolic syndrome, treatment of elevated triglyceride levels, chylomicronemia, hyperlipoproteinemia; hyperlipidemia, especially mixed hyperlipidemia; hypercholesterolemia, dysbetalipoproteinemia, hypertriglyceridemia including both the sporadic and familial disorder (inherited hypertriglyceridemia), migraine, obesity, arthritis, hypertension, arrhythmia, ulcer, learning, memory and attention deficits, cognition disorders, neurodegenerative diseases, demyelinating diseases, addiction to drugs and chemical substances including cocaine, amphetamine, ethanol and nicotine, tardive diskinesia, ischemic stroke, epilepsy, stroke, depression, stress, psychotic condition, schizophrenia; inflammation, autoimmune diseases or cancer; disorders of food ingestion, the regulation of appetite, for the reduction, increase or maintenance of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes, preferably type II diabetes caused by obesity.

### Claim 48 (depends on 27)

The method according to claim 27, wherein the disease is pain, especially neuropathic pain, inflammatory pain or other pain conditions, allodynia and/or hyperalgesia, especially mechanical allodynia.
